Patent US4582835A successfully refreshed from Google Patents.
US4582835A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Analgesic compositions
Assignee: Reckitt Benckiser Healthcare UK Ltd
•
Filing: 1984-12-05
•
Granted: 1986-04-15
•
Expires: 2004-12-05
Abstract
Abstract A method of treating pain which comprises the administration to a patient of a parenterally or sublingually effective dose of buprenorphine together with an amount of naloxone sufficient to prevent substitution in an opiate dependent subject. Preferably when the administration is parenteral the weights of naloxone and buprenorphine are within the ratio of 1:3 to 1:1 and when administered sublingually the weights are within the ratio of 1:2 to 2:1.
Inventors
- 👤 John W. Lewis
- 👤 John G. Lloyd-Jones
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 21:49
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0053; A61K9/0056; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/485; A61K9/0019; A61P; A61P25/00; A61P25/04; A61P43/00
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
64 words
A method of treating pain which comprises the administration to a patient of a parenterally effective unit dosage of buprenorphine wherein the weight of buprenorphine is between about 0.3 to about 0.6 mg and simultaneously an amount of naloxone sufficient to prevent substitution in an opiate dependent subject, the weights of naloxone and buprenorphine administered parenterally being within the ratio of 1:3 to 1:1.
Claim 2
Independent Claim
64 words
A method of treating pain which comprises the administration to a patient of a parenterally effective unit dosage of buprenorphine wherein the weight of buprenorphine is between about 0.3 to about 0.6 mg and simultaneously an amount of naloxone sufficient to prevent substitution in an opiate dependent subject, the weights of naloxone and buprenorphine administered parenterally being within the ratio of 1:3 to 1:1.
Claim 3
Independent Claim
64 words
A method of treating pain which comprises the administration to a patient of a sublingually effective unit dosage of buprenorphine wherein the weight of buprenorphine is between about 0.1 to about 0.6 mg and simultaneously an amount of naloxone sufficient to prevent substitution in an opiate dependent subject, the weights of naloxone and buprenorphine administered sublingually being within the ratio of 1:2 to 2:1.
Claim 4
Independent Claim
64 words
A method of treating pain which comprises the administration to a patient of a sublingually effective unit dosage of buprenorphine wherein the weight of buprenorphine is between about 0.1 to about 0.6 mg and simultaneously an amount of naloxone sufficient to prevent substitution in an opiate dependent subject, the weights of naloxone and buprenorphine administered sublingually being within the ratio of 1:2 to 2:1.
Claim 5
Dependent Claim
62 words
An analgesic composition in parenteral unit dosage form comprising an active dose of buprenorphine of from about 0.3 to about 0.6 mg and an amount of naloxone sufficient to prove aversive to a narcotic addict by parenteral administration but insufficient to compromise the analgesic action of the buprenorphine, the weights of naloxone and buprenorphine being within the ratio of 1:3 to 1:1.
Claim 6
Dependent Claim
62 words
An analgesic composition in parenteral unit dosage form comprising an active dose of buprenorphine of from about 0.3 to about 0.6 mg and an amount of naloxone sufficient to prove aversive to a narcotic addict by parenteral administration but insufficient to compromise the analgesic action of the buprenorphine, the weights of naloxone and buprenorphine being within the ratio of 1:3 to 1:1.
Claim 7
Dependent Claim
62 words
An analgesic composition in sublingual unit dosage form comprising an active dose of buprenorphine of from about 0.1 to about 0.6 mg and an amount of naloxone sufficient to prove aversive to a narcotic addict by parenteral administration but insufficient to compromise the analgesic action of the buprenorphine, the weights of naloxone and buprenorphine being within the ratio of 1:2 to 2:1.
Claim 8
Dependent Claim
62 words
An analgesic composition in sublingual unit dosage form comprising an active dose of buprenorphine of from about 0.1 to about 0.6 mg and an amount of naloxone sufficient to prove aversive to a narcotic addict by parenteral administration but insufficient to compromise the analgesic action of the buprenorphine, the weights of naloxone and buprenorphine being within the ratio of 1:2 to 2:1.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-04-14 | 1989-10-14 | 1990-04-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-04-14 | 1993-10-14 | 1994-04-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-04-14 | 1997-10-14 | 1998-04-15 | $7700.00 | Window Closed / Lapsed |